| Protocol-driven costs in trial-based pharmacoeconomic analyses. | |
| | |
MedLine Citation:
|
PMID: 22098282 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
Many authors and guidelines have proposed to exclude protocol-driven costs from cost-effectiveness analyses alongside clinical trials because they do not occur in clinical practice. This article, however, argues that only costs to improve patient adherence can be excluded, as the underlying protocol-driven activities have a clearly distinguishable cost and utility impact (most of the time). All other protocol-driven costs need to be included because the cost and utility impact of the underlying protocol-driven activities cannot be easily separated. |
| | |
Authors:
|
Afschin Gandjour |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Expert review of pharmacoeconomics & outcomes research Volume: 11 ISSN: 1744-8379 ISO Abbreviation: Expert Rev Pharmacoecon Outcomes Res Publication Date: 2011 Dec |
Date Detail:
|
Created Date: 2011-11-21 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101132257 Medline TA: Expert Rev Pharmacoecon Outcomes Res Country: England |
Other Details:
|
Languages: eng Pagination: 673-5 Citation Subset: IM |
Affiliation:
|
Frankfurt School of Finance and Management, Frankfurt, Germany. a.gandjour@fs.de. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The relevance of severity scores in predicting outcome after cardiac arrest.
Next Document: Advancing PROMIS's methodology: results of the Third Patient-Reported Outcomes Measurement Informati...